Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for August 4, 2021

8/3/2021

 
Regulatory Update
 
The FDA approved anifrolumab (Saphnelo, AstraZeneca), on 8/2/2021, for the treatment of moderate to severe systemic lupus erythematosus (SLE). Anifrolumab will compete with belimumab (Benlysta).
 
The FDA accepted the BLA for Roche’s faricimab for the treatment of neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME) suggesting a PDUFA date of 1/28/2022.
 
The EMA gave PRIME status to Mustang Bio’s MB-107 for the treatment of X-linked severe combined immunodeficiency in newly diagnosed infants.
 
Announced Research Updates
 
A new draft report from ICER reviewing efgartigimod and eculizumab for the treatment of myasthenia gravis found moderate certainty of a comparable, small, or substantial net health benefit for efgartigimod compared to eculizumab due to uncertainties about dosing and long-term benefits. When estimating pricing ICER found the drugs to be cost effective at an estimated price of $21,800 for efgartigimod and $19,500 for eculizumab to achieve a $150,000 per quality of adjusted life year (QALY). This compares to the current list price of $653,100 with a discounted price of $470,000 for eculizumab
 
Published Research Updates
 
In a 14.7 month, 31 patient, open-label, Phase II trial, treatment with penpulimab plus anlotinib resulted in an objective response rate of 31% in Chinese patients with unresectable hepatocellular carcinoma.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.